Compare Abbott Laboratories (ABT) vs Consolidated Edison, Inc. (ED) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Consolidated Edison, Inc. — how do they compare? Abbott Laboratories trades at $95.24 (market cap $166.94B), while Consolidated Edison, Inc. trades at $113.15 (market cap $41.64B). The key difference: Abbott Laboratories is far larger — about 4× Consolidated Edison, Inc.'s market cap, and Consolidated Edison, Inc. pays the higher dividend (3.08%). Which is the better fit depends on your goals.
| ABT | ED | |
|---|---|---|
Market Cap | $166.94B | $41.64B |
Sector | Health | Utilities |
52-Week High | $136.62 | $115.46 |
52-Week Low | $82.57 | $95.37 |
Enterprise Value | $193.69B | $68.67B |
Dividend Yield | 2.63% | 3.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Consolidated Edison (ED) trades at $112.99, down 0.88% on the day, with a bullish technical signal from moving averages. The utility company reported mixed Q1 2026 earnings but maintains steady revenue growth and a 12.52% net income margin. Recent news highlights grid upgrades and a new $2 billion equity offering program announced May 8, 2026.
ED offers stable dividend income with a 52-year growth streak but faces analyst caution with 63% hold ratings. Upside potential exists from infrastructure investments, while risks include debt levels and regulatory pressures. The consensus price target of $103.50 suggests limited near-term appreciation from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Consolidated Edison, Inc.
Con Ed is a holding company for Consolidated Edison of New York, or CECONY, and Orange & Rockland, or O&R. These utilities provide steam, natural gas, and electricity to customers in southeastern New York—including New York City—and small parts of New Jersey. The two utilities will generate nearly all of Con Ed's earnings once it closes the sale of its clean energy business to RWE. Con Ed's clean energy business owns the second-largest portfolio of utility-scale solar projects in the U.S. Following the sale, Con Ed's only non-utility earnings will come from investments in gas and electric transmission.
Read more on ED →
